Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$17.39 ▲ +1.33
(+8.28%)
MKT CAP: $1.65B • VOL: 5.15M
52W L $2 52W H $18
ROARABLE / RQD
D • 46/100
PIOTROSKI
3 / 9
REPL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$319.9M | -$261.6M | -$234.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$313.9M | -$247.3M | -$215.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$280.3M | -$192.3M | -$185.5M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$280.3M | -$192.3M | -$185.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $123.0M | $172.2M | — |
| Total Debt (Short + Long Term) | $47.6M | $46.0M | — |
| Total Stockholders' Equity | $210.5M | $482.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR REPL.